# A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Impact of CLB101TM️ on Gut Health in Healthy, Overweight Individuals

> **NCT07336615** · NA · ENROLLING_BY_INVITATION · sponsor: **ClostraBio Inc.** · enrollment: 48 (estimated)

## Conditions studied

- Gastrointestinal
- Overweight , Obesity

## Interventions

- **DIETARY_SUPPLEMENT:** CLB101™️
- **OTHER:** Placebo
- **DIETARY_SUPPLEMENT:** CLB101™️
- **OTHER:** Placebo control

## Key facts

- **NCT ID:** NCT07336615
- **Lead sponsor:** ClostraBio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-10-09
- **Primary completion:** 2026-04-26
- **Final completion:** 2026-06-26
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07336615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07336615, "A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Impact of CLB101TM️ on Gut Health in Healthy, Overweight Individuals". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07336615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*